Indefinite Delivery Contract 75D30123D15809
Award Date
12/31/22
Last Date to Order
2/28/24
Federal Agency
CDC Pittsburgh
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides for pediatric flu vaccines for the 2023-2024 period. The multiple award contract has a potential value of $220.5 million and was awarded to Seqirus USA Inc. on December 31, 2022. The contract aims to procure pediatric flu vaccines through February 28, 2024 to support the Centers for Disease Control and Prevention's efforts in preventing the spread...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to provide pediatric flu vaccines for the 2020-2021 season. The contract has a potential value of $140.25 million and was awarded to Glaxosmithkline, LLC on January 7, 2020, with an ordering period through February 28, 2021. The original solicitation sought proposals to supply between 60-80 million doses of pediatric flu vaccines for nationwide delivery....
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
This multiple award IDV was issued by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to procure pediatric flu vaccines for 2023-2024. Sanofi Pasteur Inc. is the prime contractor awarded under the $153.88 million potential value contract. The IDV aims to deliver pediatric flu vaccines through task orders or price lists issued against the master agreement prior to the February 2024 ordering deadline. As the CDC works to prevent pediatric...
The Centers for Disease Control and Prevention awarded a single award indefinite delivery contract to Seqirus USA Inc. with a potential value of $180,705,000. The contract aims to procure pediatric influenza vaccines for children ages 0 through 18 years old to support immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. Task orders will be issued against the contract to purchase required vaccines each flu season through February 28,...
The Centers for Disease Control and Prevention (CDC) has awarded Astrazeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, an Indefinite Delivery Contract worth up to $75.52 million to provide pediatric influenza vaccines for the 2022-2023 season. The contract has a period of performance from January 5, 2022 through February 28, 2023. Under this contract, Astrazeneca will deliver between 100 doses to 50 million doses of influenza vaccine for children ages 0 through 18 to CDC...
This multiple award IDV was issued by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to procure pediatric flu vaccines for the 2023-2024 flu season. Glaxosmithkline, LLC was awarded the IDV as prime contractor. The IDV does not include any set-asides and has a potential value of $174.9 million. Orders may be placed through February 2024 to deliver pediatric flu vaccines in support of the CDC's efforts to increase vaccination rates among...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Seqirus USA Inc. for adult flu vaccines for 2023-2024. The potential value of the contract is $146,103,060. Orders may be placed through February 28, 2024. The contract aims to procure adult flu vaccines to support the CDC's efforts in disease prevention. As the leading public health agency in the United States, the CDC works to control and prevent...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, on December 31, 2024. The contract has a ceiling value of $51,900,000 and a period of performance through February 28, 2026. The primary purpose of this IDV is to procure pediatric influenza vaccines for the 2025-2026 season. AstraZeneca, as the prime contractor, will provide these vaccines to the CDC and potentially...